L-Dox

20 mg

50 mg

• Generic Name: Liposomal Doxorubicin Hydrochloride

• Brand Name: L-Dox

• Dosage Form: Sterile Liposomal Injection

• Common Strengths: 20 mg/10 ml, 50 mg/25 ml vials (may vary by manufacturer)

• Route of Administration: Intravenous (IV) infusion

• Therapeutic Class: Antineoplastic (Anthracycline Antibiotic)

Indications:

• Ovarian cancer (in patients with disease progression following platinum-based chemotherapy)

• AIDS-related Kaposi's sarcoma

• Multiple myeloma (in combination with bortezomib)

• Breast cancer and other solid tumors (off-label in some cases)

Key Features:

• Liposomal encapsulation helps to prolong circulation time in the blood.

• Preferential accumulation in tumor tissues through the Enhanced Permeability and Retention (EPR) effect.

• Reduces cardiotoxicity compared to conventional doxorubicin.

• Controlled and targeted drug release.

Mechanism of Action:

Doxorubicin intercalates into DNA, inhibiting topoisomerase II activity and generating free radicals, leading to apoptosis of cancer cells.

Common Side Effects:

• Fatigue

• Nausea and vomiting

• Mucositis

• Palmar-plantar erythrodysesthesia (hand-foot syndrome)

• Myelosuppression

• Less cardiotoxicity compared to conventional doxorubicin but still possible with cumulative dosing.